( September 24, 2025, 2:31 PM EDT) -- BOSTON — A Massachusetts federal judge on Sept. 23 dismissed a qui tam relator’s suit alleging violations of the federal False Claims Act (FCA) and related state laws regarding pharmaceutical companies’ purported fraudulently obtained patents for the drug Xyrem resulting in government health insurers reimbursing Xyrem prescriptions “at inflated prices,” finding that facts in the complaint were previously disclosed and that the public disclosure bar applies....